The real pressure caused by the presumed overabundance of cancer research falls on investors and decision makers who guide R&D portfolios.
from Forbes Real Time https://www.forbes.com/sites/johnlamattina/2018/04/24/is-biopharma-investing-too-much-in-cancer-rd/
via IFTTT
No comments:
Post a Comment